Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations

Bibliography

• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;13:e442
   Google Scholar
• Chobhanian AV, Bakris GL, Black HR, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of high blood pressure (The JNC 7 report). JAMA 2003;89:2560-72
   Google Scholar
• Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension 1988 – 2008. JAMA 2010;303:2043-50.
   PubMed Web of Science ®Google Scholar
• Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment and control – continued disparities in adults: United States, 2005 – 2006. NCHS Data Brief 2008;3:1-8
   PubMedGoogle Scholar
• Ong KL, Cheung BMY, Man BY, Pravalence, awareness, treatment, and control of hypertension among United States adults 1999 – 2004. Hypertension 2007;49:69-75
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
   PubMed Web of Science ®Google Scholar
• Mazzaglia G, Ambrosioni E, Alacqua M, Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605
   PubMed Web of Science ®Google Scholar
• Dragomir A, Cote R, Roy L, Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010;48:418-25
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009;11:376-82
   PubMed Web of Science ®Google Scholar
• Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich) 2010;12:40-6
   PubMed Web of Science ®Google Scholar
• Fung V, Huang J, Brand R, Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29:972-84
   PubMed Web of Science ®Google Scholar
• Maron DJ, Boden WE, O'Rourke RA, COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2010;55:1348-58
   PubMed Web of Science ®Google Scholar
• Benner JS, Chapman RH, Petrilla AA, Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 2009;66:1471-7
   PubMed Web of Science ®Google Scholar
• Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomised controlled trials. Arch Intern Med 2004;164:722-32
   PubMed Web of Science ®Google Scholar
• Conn VS, Hafdahl AR, Cooper PS, Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomised controlled trials. Gerontologist 2009;49:447-62
   PubMed Web of Science ®Google Scholar
• Feldman RD, Zou GY, Vandervoort MK, A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-53
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, for The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
   PubMed Web of Science ®Google Scholar
• Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 2009;30:2427-30
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Katragadda S, Arora RR. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 2010;17:e11-23
   PubMedGoogle Scholar
• Gupta M, Honos GN, Velazquez EJ, Evidence for the efficacy of ARBs across the cardiovascular continuum. Curr Med Res Opin 2010;26:1203-18.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de ZD, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Kjeldsen SE, Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011;12:65-82
   PubMed Web of Science ®Google Scholar
• ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 2011;29:623-35
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 2009;122:356-65
   PubMed Web of Science ®Google Scholar
• Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-9
   PubMed Web of Science ®Google Scholar
• Bangalore S, Wild D, Parkar S, Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008;52:1062-72
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008;117:2706-15
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Messerli FH. Beta-blockers: no longer an option for uncomplicated hypertension. Curr Cardiol Rep 2007;9:441-6
   PubMedGoogle Scholar
• Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50:563-72
   PubMed Web of Science ®Google Scholar
• Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press 2008;17(Suppl 1):32-40
   Web of Science ®Google Scholar
• Corrao G, Zambon A, Parodi A, Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819-24
   PubMed Web of Science ®Google Scholar
• Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68(9):1207-25
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010;123:1016-30
   PubMed Web of Science ®Google Scholar
• Kronish IM, Woodward M, Sergie Z, Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011;123:1611-21
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, ASH position article: combination therapy in hypertension. J Am Soc Hypertens 2010;4:90-8
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Flack JM, Sica DA, Bakris G, Management of High Blood Pressure in Blacks. An update of the International society on hypertension in blacks consensus statement. Hypertension 2010;56:780-800
   PubMed Web of Science ®Google Scholar
• Littlejohn TW III, Majul CR, Olvera R, Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:207-13
   PubMed Web of Science ®Google Scholar
• Littlejohn TW III, Majul CR, Olvera R, Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med 2009;121:5-14
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith TR, Glazer R, Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80
   PubMed Web of Science ®Google Scholar
• Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomised prospective intervention study in a large population of hypertensive patients. J Clin Hypertens 2006;8:634-41
   PubMedGoogle Scholar
• Wald DS, Law M, Morris JK, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• White WB, Littlejohn TW, Majul CR, Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010;15:205-12
   PubMed Web of Science ®Google Scholar
• NICE Guidelines. Available from: http://guidance.nice.org.uk/CG127 [ Accessed August 2011
   Google Scholar
• Makani H, Bangalore S, Romero J, Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011;124:128-35
   PubMed Web of Science ®Google Scholar
• Fogari R, Malamani G, Zoppi A, Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther 2007;29:413-18
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Derosa G, Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4
   PubMed Web of Science ®Google Scholar
• Fogari R†, Zoppi A, Maffioli P, Lazzari P. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opin Pharmacother 2011;12(16):2441-8
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly. Am J Cardiovasc Drugs 2008;8:45-50
   PubMed Web of Science ®Google Scholar
• Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-83
   PubMed Web of Science ®Google Scholar
• Zeng F, Patel BV, Andrews L, Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010;26:2877-87
   PubMed Web of Science ®Google Scholar
• Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin Exp Hypertens 2010;32:35-42
   PubMed Web of Science ®Google Scholar
• Chrysant SG. The role of angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs 2010;10:315-20
   PubMed Web of Science ®Google Scholar
• Neldam S, Lang M, Jones R, on behalf of the TEAMSTA-5 Investigators. Telmisartan and amlodipine single-pill combinations versus amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. J Clin Hypertens 2011;13(7):459-66
   Web of Science ®Google Scholar
• Neldam S, Edwards C, Jones R, on behalf of the TEAMSTA-10 Investigators. Long-term efficacy and safety profile of single-pill combinations of telmisartan/amlodipine in patients not controlled on amlodipine 10 mg: open-label follow-up of teamsta-10: Pp.27.90. J Hypertens 2010;28:e474
   Google Scholar
• Littlejohn, TW III, Chrysant SG, Webster D, Efficacy of telmisartan in combination with amlodipine in obese hypertensive patients: sub-analysis from a factorial design study. J Clin Hypertens 2009;11(Suppl A):A158
   Google Scholar
• Littlejohn T, Ruilope LM, Raskin P, Telmisartan in combination with amlodipine provides a highly effective and well tolerated treatment option for hypertensive patients with diabetes: sub-analysis from a factorial design study. J Hypertens 2009;27(Suppl 4);S275
   PubMedGoogle Scholar
• Chrysant SG, Lee J, Melino M, Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 2010;24:730-8
   PubMed Web of Science ®Google Scholar
• Neutel JM, Mancia G, Black HR, Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA Severe HTN Study [abstract]. J Clin Hypertens 2010;12(Suppl7):537
   Google Scholar
• Jamerson K, Bakris GL, Dahlof B, ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16:80-6
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
   PubMed Web of Science ®Google Scholar